Recruiting EARLY_PHASE1 Reflux Disease

New treatment option for Reflux Disease

Official title Development of a Preparation for Supportive Supplementation of Probiotics in Patients With Reflux

ClinicalTrials.gov ID: NCT07600008

What this study is testing

What it's testing
A two-arm, double-blind, randomized, placebo-controlled study investigating the efficacy of a probiotic preparation developed as supportive supplementation of probiotics in patients with reflux. The objective of this trial is to evaluate the effect of the probiotic dietary supplement on the diversity and composition of the gut microbiome in patients diagnosed with GERD who are on PPI therapy.
  • Phase 1: an early, usually small safety study
  • Time commitment: about 6 weeks
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 40 to 55

You may be able to join if

  • Diagnosed GERD.
  • Stable health without current complications.
  • Patients on stable pharmacological PPI therapy (rabeprazole).

You likely can't join if

  • Use of probiotics or prebiotics within the last 4 weeks.
  • Pregnancy or breastfeeding.
  • Systemic antimicrobial therapy within the last 4 weeks.
  • Infectious disease of the respiratory or gastrointestinal tract within the last 2 weeks.
  • Serious chronic disease that could affect study results, including cancer, diabetes, inflammatory bowel disease, diagnosed SIBO.
  • Prior surgeries, especially fundoplication and resections of the esophagus or stomach.
See the full eligibility criteria
Who can join
  • Diagnosed GERD.
  • Stable health without current complications.
  • Patients on stable pharmacological PPI therapy (rabeprazole).
What rules you out
  • Use of probiotics or prebiotics within the last 4 weeks.
  • Pregnancy or breastfeeding.
  • Systemic antimicrobial therapy within the last 4 weeks.
  • Infectious disease of the respiratory or gastrointestinal tract within the last 2 weeks.
  • Serious chronic disease that could affect study results, including cancer, diabetes, inflammatory bowel disease, diagnosed SIBO.
  • Prior surgeries, especially fundoplication and resections of the esophagus or stomach.
  • Patients with psychiatric or cognitive disorders.
  • Hypersensitivity to components of the investigational product.

The study team makes the final eligibility decision.

Where it's taking place

  • Olomouc, Czechia

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The study runs about 6 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.

Who can join this trial?

This study is enrolling all sexes, 40 years to 55 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Olomouc, Czechia. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.